Bevacizumab for treating persistent, recurrent or metastatic cervical cancer

Published on 01 Apr 2022
Last Updated on 12 Jul 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended bevacizumab reference biologic (Avastin) for subsidy for treating persistent, recurrent or metastatic cervical cancer in view of unfavourable cost effectiveness compared with bevacizumab biosimilar (Mvasi) at the price proposed by the manufacturer.

Clinical indications, subsidy class and MediShield Life claim limits are provided in the Annex.

Bevacizumab for treating persistent recurrent or metastatic cervical cancer (12 Jul 22) [PDF, 132 KB]

Bevacizumab for treating advanced cervical cancer PES (1 Apr 2022) [PDF, 126 KB]